The global demand for highly potent drugs is growing rapidly, with the market projected to reach $46.9B by 2030, driven by innovations in drug delivery technologies, regulatory advancements, and the rising need for personalized treatments. The oncology sector has been a key witness to this, experiencing substantial growth due to the increasing adoption of small molecules, conjugates, and other targeted therapies.